Combining multi-omics and drug perturbation profiles to identify novel treatments that improve disease phenotypes in spinal muscular atrophy
Keyword(s):
ABSTRACTSpinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the lead candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including SMN expression and lifespan. Our work highlights the potential of multiple, parallel data driven approaches for development of novel treatments for use in combination with SMN restoration therapies.
2020 ◽
Vol 21
(9)
◽
pp. 3297
◽
2014 ◽
Vol 24
(11)
◽
pp. 973-977
◽
Keyword(s):
2016 ◽
Vol 10
◽
pp. JEN.S33122
◽
2008 ◽
Vol 28
(22)
◽
pp. 6929-6938
◽
Keyword(s):
2018 ◽
Vol 29
(2)
◽
pp. 96-110
◽
2020 ◽
Vol 13
◽
pp. 175628642097995
2008 ◽
Vol 175
(1)
◽
pp. 36-43
◽
Keyword(s):